Current Lawsuits: Hernia Mesh | Depuy Pinnacle Hip | Stryker Hip | Other Metal Hip | Taxotere | Talcum Powder
Personal Injury Lawyer -

Free case review

facebook logo google+ logo twitter logo youtube logo

Viibryd lawsuit

viibryd pill containers

Viibryd Lawsuit

No New Viibryd Liability Litigation, Allergan Reports

The attorneys at are investigating potential lawsuits involving Viibryd and acute pancreatitis, as well as pancreatic cancer.

Despite growing concerns over health risks associated with its antidepressant Viibryd, Allergan PLC did not disclose any ongoing product-liability lawsuits over the drug in its latest quarterly financial report, which was filed with the United States Securities and Exchange Commission (SEC) on August 3, 2018.

In its SEC Form 10-Q covering the period ended June 30, 2018, Allergan included the mandatory disclosure of potential legal risks and liabilities faced by the company and its subsidiaries. While the “Product Liability Litigation” section referenced ongoing legal matters involving half-a-dozen Allergan products, Viibryd was not among them.

Allergan similarly did not disclose any ongoing or pending product-liability litigation involving Viibryd during its annual financial disclosures for the year ended December 31, 2017.

Viibryd was, however, included in a list of “Patent Enforcement Matters” under the “Patent Litigation” section of both reports. The company’s litigation risks are buried deep in the Notes to Financial Statement under Note 19 of the quarterly report and Note 24 of the annual report.

The products for which Allergan does disclose active product-liability litigation in its most recent SEC filing include: Actonel (168 active cases, 353 unfiled potential claims); Alloderm (370 active cases); Benicar (1,759 actions); Celexa/Lexapro (166 actions), Repliform (325 cases), and AndroDerm (525 pending actions). (All figures and descriptors are as reported by Allergen to the SEC.)

Viibryd was approved in 2011 by the US Food and Drug Administration (FDA) as a treatment for major depressive disorder (MDD). While the label was revised as recently as January 2017 to add the risk of Serotonin Syndrome to the “Warnings and Precautions” section, a growing body of evidence increasingly has associated the use of Viibryd with serious problems of pancreas, including pancreatitis and pancreatic cancer.

As of the January 2017 revision, the FDA-approved label for Viibryd contains no mention of the any pancreas-related risks.

If you or a loved one has suffered from pancreatitis or pancreatic cancer after taken Ziibryd, contact the experienced team of attorneys at right away for a free legal consultation with an attorney!


US Securities and Exchange Commission (SEC) Form 10-Q – “Allergan” — For the Six Months Ended June 30, 2018 Note 19 – Commitments and Contingencies
Form 10-K – “Allergan PLC” — For the 12 Months Ended December 31, 2017 Note 24 – Commitments and Contingencies
US Food and Drug Administration (FDA) Medication Guide – “Viibryd” (Revised 1/2017)

Talk with aN Attorney now!

Viibryd Lawsuit

The attorneys at are investigating potential lawsuits involving Viibryd and acute pancreatitis, as well as pancreatic cancer. is not aware of any lawsuits having been filed yet regarding the link between Viibryd and pancreatitis or pancreatic cancer. However, in December 2016 Forest Laboratories entered into a settlement agreement with the federal government and multiple state Medicaid programs. Forest paid $38 million dollars to settle claims that Forest paid physicians to prescribe Viibryd to their patients. This kind of behavior by the company makes us suspicious. What did they know about the link between Viibryd and pancreatitis and pancreatic cancer before they were forced to warn?

In our experience when new warning labels are added, users of Viibryd will likely come forward with complaints of pancreatitis and pancreatic cancer. We are not sure yet why Viibryd causes problems with the pancreas but this drug is different from other SSRIs in that it is the only one containing a 5HT1A receptor partial agonist.  This may be the causative element. Lawyers at are actively investigating and researching this issue.

Our initial research indicates that the highest incidence of Pancreatitis in Viibyrd users may be among women who are 50-59 years old, have been taking the drug for more than one 1 month and also take the medication Gabapentin. An online study we reviewed showed that, of 4,514 people who had side effects while taking Viibryd, 11 had pancreatitis. Given the popularity of Viibryd, we expect these numbers are very low, as not every case of pancreatitis or pancreatic cancer was reported, especially before the FDA warning.

We expect that users of Viibyrd who suffered pancreatitis or pancreatic cancer will now start coming forward.

Viibryd patients who suffer acute pancreatitis or pancreatic cancer will likely incur significant physical, financial and emotional damages due to their illness. While money cannot replace health, filing a Viibryd lawsuit can help victims be compensated for medical bills, pain and suffering, lost wages and emotional distress.

If you, or a loved one, took Viibryd and suffered pancreatitis, or pancreatic cancer, contact the lawyers at immediately for a free consultation.

Click Viibryd Letter To Read The Letter To The Manufacturer Of Viibryd

Talk with aN Attorney now!

Articles Related To: Bad Drugs

Viibryd Side Effects

Big Pharma Marketing

Free Case Review

Free Case Review